author-photo

Christoph Reinhard

Eli Lilly and Company

84

Papers

8059

Citations

Citation Trend

Filter By

Papers (60) Sort By

Journal Conference Others

Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer

2021 Frontiers in Cell and Developmental Biology
Show All
- Source
- Cite
- Save
Citations (0)
Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evently Distributed

2021 Cells
Show All
- Source
- Cite
- Save
Citations (1)
Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.

2020
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1699: IMMUcan: Broad cellular and molecular profiling of the human tumor microenvironment

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis.

2020 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (6)
Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

2019
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Aurora A selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells and shows potent preclinical antitumor efficacy

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (14)
Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene.

2019 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (75)
Abstract LB-083: Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity inKRASmutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)